Genscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026

Bulletin Express

04/14

Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI® during the quarter ended 31 March 2026. The figure was disclosed in Legend’s Form 6-K filed with the U.S. Securities and Exchange Commission on 14 April 2026 (New York time).

According to the filing, the sales data were provided to Legend by collaboration partner Janssen Biotech, Inc. under their December 2017 Collaboration and License Agreement. Genscript and Legend have not independently verified the numbers.

Legend Biotech, listed on the Nasdaq Global Select Market via American Depositary Shares, had previously released preliminary CARVYKTI® sales data for the quarter ended 31 December 2025 on 21 January 2026.

The announcement reiterates forward-looking statement cautions, citing potential risks such as clinical outcomes, regulatory actions, intellectual property challenges, and competitive pressures, as outlined in Legend’s Form 20-F filed on 10 March 2026.

Genscript’s board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1188331019"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188331019\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188331019?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188331019","market":"us","top_or_hot":-1,"title":"Genscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026","media":"Bulletin Express","content":"<p>Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI® during the quarter ended 31 March 2026. The figure was disclosed in Legend’s Form 6-K filed with the U.S. Securities and Exchange Commission on 14 April 2026 (New York time).</p>\n<p>According to the filing, the sales data were provided to Legend by collaboration partner Janssen Biotech, Inc. under their December 2017 Collaboration and License Agreement. Genscript and Legend have not independently verified the numbers.</p>\n<p>Legend Biotech, listed on the Nasdaq Global Select Market via American Depositary Shares, had previously released preliminary CARVYKTI® sales data for the quarter ended 31 December 2025 on 21 January 2026.</p>\n<p>The announcement reiterates forward-looking statement cautions, citing potential risks such as clinical outcomes, regulatory actions, intellectual property challenges, and competitive pressures, as outlined in Legend’s Form 20-F filed on 10 March 2026.</p>\n<p>Genscript’s board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-04-14 20:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI® during the quarter ended 31 March 2026. The figure was disclosed in Legend’s Form 6-K filed with the U.S. Securities and Exchange Commission on 14 April 2026 (New York time).</p>\n<p>According to the filing, the sales data were provided to Legend by collaboration partner Janssen Biotech, Inc. under their December 2017 Collaboration and License Agreement. Genscript and Legend have not independently verified the numbers.</p>\n<p>Legend Biotech, listed on the Nasdaq Global Select Market via American Depositary Shares, had previously released preliminary CARVYKTI® sales data for the quarter ended 31 December 2025 on 21 January 2026.</p>\n<p>The announcement reiterates forward-looking statement cautions, citing potential risks such as clinical outcomes, regulatory actions, intellectual property challenges, and competitive pressures, as outlined in Legend’s Form 20-F filed on 10 March 2026.</p>\n<p>Genscript’s board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1188331019","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188331019","pubTimestamp":1776168205,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI®...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞：传奇生物斥资5.97亿美元收购CARVYKTI®2026年第一季度净销售额","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI® during the quarter ended 31 March 2026. The figure was disclosed in Legend’s Form 6-K filed with the U.S. Securities and Exchange Commission on 14 April 2026 (New York time).\nAccording to the filing, the sales data were provided to Legend by collaboration partner Janssen Biotech, Inc. under their December 2017 Collaboration and License Agreement. Genscript and Legend have not independently verified the numbers.\nLegend Biotech, listed on the Nasdaq Global Select Market via American Depositary Shares, had previously released preliminary CARVYKTI® sales data for the quarter ended 31 December 2025 on 21 January 2026.\nThe announcement reiterates forward-looking statement cautions, citing potential risks such as clinical outcomes, regulatory actions, intellectual property challenges, and competitive pressures, as outlined in Legend’s Form 20-F filed on 10 March 2026.\nGenscript’s board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}